文献速递临床试验与 GCP新药、器械与细胞基因治疗研发

亚甲蓝治疗难治性感染性休克的有效性:多中心、随机、安慰剂对照试验的研究方案

Efficacy of methylene blue in refractory septic shock: study protocol for a multicenter, randomized, placebo-controlled trial.
PubMed 文献 · Trials · 2024-09-27

本研究为多中心、随机、安慰剂对照试验,计划纳入100例难治性感染性休克患者,评估亚甲蓝作为辅助治疗的安全性及有效性。干预方案为先静脉推注2 mg/kg亚甲蓝,随后以0.5 mg/kg/h持续输注48小时。主要结局为前48小时难治性感染性休克所需血管加压药的总剂量。

要点

  • 多中心、随机、安慰剂对照试验,计划纳入100例难治性感染性休克患者。
  • 亚甲蓝用法:静脉推注2 mg/kg后,以0.5 mg/kg/h持续输注48小时。
  • 主要结局为前48小时难治性感染性休克所需血管加压药的总剂量。

核心结论

  • 本方案旨在评估亚甲蓝作为难治性感染性休克辅助治疗的安全性及有效性。
  • 主要结局指标为血管加压药需求及血流动力学参数。
  • 结果旨在为难治性感染性休克中亚甲蓝的安全性和有效性提供证据,指导临床决策。

研究设计与样本

  • 多中心、随机、安慰剂对照试验,计划纳入100例难治性感染性休克患者。
  • 干预方案为先静脉推注2 mg/kg亚甲蓝,随后以0.5 mg/kg/h持续输注48小时。
  • 主要结局为前48小时难治性感染性休克所需血管加压药的总剂量。
  • 次要结局包括其他血流动力学参数、氧代谢指标、组织灌注指标、主要器官功能指标及某些血浆细胞因子和其他因子。
  • 该临床试验已于2023年3月16日在中国临床试验注册中心(ChiCTR)注册,注册号为ChiCTR2300069430。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Septic shock is now the leading cause of mortality in intensive care units (ICUs). Refractory septic shock requires high doses of vasopressors. Some previous studies have revealed that methylene blue could improve hypotension status and help reduce the dosage of catecholamines. This study aims to investigate the clinical effect of methylene blue in septic shock and explore whether it can increase arterial pressure and reduce the usage of vasopressors. METHODS: This study is a multicenter, randomized, placebo-controlled trial planning to include 100 refractory septic shock patients. The protocol is to administer a bolus of 2 mg/kg methylene blue intravenously followed by a continuous infusion of 0.5 mg/kg/h for 48 h. The primary outcome is the total dose of vasopressor required in refractory septic shock in the first 48 h. Secondary outcomes include other hemodynamic parameters, oxygen metabolism indexes, tissue perfusion indexes, major organ function indexes, and certain plasma cytokines and other factors. DISCUSSION: This protocol aims to evaluate the safety and efficacy of methylene blue as adjuvant therapy for refractory septic shock. The main outcome measure will be vasopressor requirements and hemodynamic parameters. Additionally, bedside ultrasonography, blood gases, and cytokines will be assessed to evaluate perfusion, respiratory, and metabolic effects. The results are intended to provide evidence on the safety and efficacy of methylene blue in refractory septic shock, guiding clinical decision-making. TRIAL REGISTRATION: This clinical trial has been registered at ChiCTR ( https://www.chictr.org.cn/ ) on March 16, 2023. ChiCTR registration number: ChiCTR2300069430.

来源:Trials,查看原文。版权归原作者所有。

引用

  1. Jia J, Ji J, Liu Z, et al. Efficacy of methylene blue in refractory septic shock: study protocol for a multicenter, randomized, placebo-controlled trial. Trials. 2024. PMID: 39334256. doi:10.1186/s13063-024-08439-5

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。